AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-36418019_ITM" title="Facts and information about Credit Suisse predicts peak sales of $2.2 bn for Genmab's Arzerra.">Credit Suisse predicts peak sales of $2.2 bn for Genmab's Arzerra.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Credit Suisse predicts peak sales of $2.2 bn for Genmab's Arzerra.
Credit Suisse believes it is most likely that the anticipated approval of Arzerra (formerly Ofatumumab) for the treatment of chronic lymphatic leukaemia will take place in mid-2009 and that sales of Arzerra will peak at $2.2 bn in 2015. It expects this will mainly be for the indications chronic lymphatic leukaemia and …
Related articles from newspapers, magazines, journals, and more
-
- Diabetes drug shines in Lilly study.
-
News wire article from: The Indianapolis Star (Indianapolis, IN)
June 12, 2006
700+ words
-
- Lilly drug would treat a top cause of blindness.
-
News wire article from: The Indianapolis Star (Indianapolis, IN)
June 11, 2006
700+ words
-
- Event Brief of Allergan, Inc. Announces Agreement to Acquire Esprit Pharma,...
-
News wire article from: Fair Disclosure Wire
September 19, 2007
700+ words
-
- Allergan, Inc. Announces Agreement to Acquire Esprit Pharma, Inc. - Final.
-
News wire article from: Fair Disclosure Wire
September 19, 2007
700+ words
-
- New Osteoporosis Drug Appears to Build Bone.
-
News wire article from: The Indianapolis Star (Indianapolis, IN)
May 10, 2001
700+ words
